News

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...
Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.
The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...
The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But ...
HIV treatment stops the HIV replication that causes immune damage. But there are places in the body where the virus "hides" ...
Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...